ISCOMATRIX (TM) adjuvant: An adjuvant suitable for use in anticancer vaccines

Stewart, Trina J., Drane, Debbie, Malliaros, Jim, Elmer, Heidi, Malcolm, Karen M., Cox, John C., Edwards, Stirling J., Frazer, Ian H. and Fernando, Germain J. P. (2004) ISCOMATRIX (TM) adjuvant: An adjuvant suitable for use in anticancer vaccines. Vaccine, 22 27-28: 3738-3743. doi:10.1016/j.vaccine.2004.03.026

Author Stewart, Trina J.
Drane, Debbie
Malliaros, Jim
Elmer, Heidi
Malcolm, Karen M.
Cox, John C.
Edwards, Stirling J.
Frazer, Ian H.
Fernando, Germain J. P.
Title ISCOMATRIX (TM) adjuvant: An adjuvant suitable for use in anticancer vaccines
Journal name Vaccine   Check publisher's open access policy
ISSN 0264-410X
Publication date 2004-09
Sub-type Article (original research)
DOI 10.1016/j.vaccine.2004.03.026
Volume 22
Issue 27-28
Start page 3738
End page 3743
Total pages 6
Editor James B. Campbell
K. Yamanishi
R. E. Spier
Place of publication United Kingdom
Publisher Elsevier
Collection year 2004
Language eng
Subject C1
320206 Tumor Immunology
730108 Cancer and related disorders
11 Medical and Health Sciences
Abstract Human Papillomavirus type 16 (HPV16) E6 and E7 oncoproteins are associated with cervical cancer development and progression and can therefore be used as target antigens for cancer immunotherapy. In this study we evaluated the immunogenicity in mice, of different vaccine formulations using recombinant HPV16 derived E6E7 or E7GST fusion proteins. When co-administered with ISCOMATRIX(TM) adjuvant, these E6E7 proteins consistently induced E7 specific CTL, in vivo tumor protection, antibody and DTH responses. ISCOMATRIX(TM) adjuvant has been developed for use in the formulation of novel human vaccines and has been evaluated for safety and toxicity in human trials. A formulation containing aluminum hydroxide (Al(OH)(3)) gave a lesser degree of E7 specific antibody, and no local E7 specific CTL response but similar DTH and tumor protection. These findings demonstrate the potential of ISCOMATRIX(TM) adjuvant to stimulate both cellular and humoral immune responses to endogenously processed target antigens, and hence is the preferred adjuvant when CTL responses are desirable. (C) 2004 Elsevier Ltd. All rights reserved.
Keyword Immunology
Medicine, Research & Experimental
Veterinary Sciences
Cancer Vaccine
Tumor Protection
Human-papillomavirus Type-16
Transforming Protein
Th2-type Responses
Q-Index Code C1

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 26 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 34 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 15 Aug 2007, 04:09:55 EST